The Biotech Growth Trust (LON:BIOG) Stock Price Down 0.2% - Here's Why

Key Points

• The Biotech Growth Trust PLC shares fell by 0.2% to GBX 832 ($10.99) during mid-day trading, with a significant increase in trading volume of 146%.
• The company has a market capitalization of £237.69 million and financial ratios including a price-to-earnings ratio of 2.79 and a debt-to-equity ratio of 11.02.
• Insiders have shown confidence in the stock, with Nicola Shepherd and Roger Yates buying a total of 10,500 shares recently at prices around GBX 747 to GBX 771.

The Biotech Growth Trust PLC (LON:BIOG - Get Free Report) dropped 0.2% during trading on Thursday . The stock traded as low as GBX 815.76 ($10.83) and last traded at GBX 832 ($11.04). Approximately 375,708 shares were traded during mid-day trading, an increase of 146% from the average daily volume of 152,891 shares. The stock had previously closed at GBX 834 ($11.07).

The Biotech Growth Trust Price Performance

The company's fifty day moving average price is GBX 756.46 and its 200 day moving average price is GBX 767.91. The company has a debt-to-equity ratio of 11.02, a quick ratio of 0.00 and a current ratio of 0.59. The firm has a market capitalization of £233.69 million, a price-to-earnings ratio of 2.75 and a beta of 0.50.

Insider Activity

In other The Biotech Growth Trust news, insider Roger Yates purchased 10,000 shares of the firm's stock in a transaction dated Wednesday, June 4th. The stock was acquired at an average cost of GBX 747 ($9.92) per share, with a total value of £74,700 ($99,150.52). Also, insider Nicola Shepherd bought 500 shares of The Biotech Growth Trust stock in a transaction on Tuesday, June 10th. The shares were purchased at an average cost of GBX 771 ($10.23) per share, with a total value of £3,855 ($5,116.80). Insiders own 0.71% of the company's stock.

About The Biotech Growth Trust

The Biotech Growth Trust seeks capital appreciation through investment in the worldwide biotechnology industry. In order to achieve its investment objective, the Company invests in a diversified portfolio of shares and related securities in biotechnology companies on a worldwide basis. Performance is measured against the NASDAQ Biotechnology Index (sterling adjusted).